Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

J Boers

Showing results (61-70 of 123) with videos related to

Pageof 13
Sort By:
Cancer Immunology, Immunotherapy : CII|March 28, 2021
Clinical outcome of patients with metastatic melanoma of unknown primary in the era of novel therapyDanielle Verver, Dirk J Grünhagen, Alexander C J van Akkooi, et al.
Cancers|May 13, 2020
Surgery for Unresectable Stage IIIC and IV Melanoma in the Era of New Systemic TherapyStephanie A Blankenstein, Maureen J B Aarts, Franchette W P J van den Berkmortel, et al.
Cancers|September 28, 2021
Sex-Based Differences in Treatment with Immune Checkpoint Inhibition and Targeted Therapy for Advanced Melanoma: A Nationwide Cohort StudyMonique K van der Kooij, Olaf M Dekkers, Maureen J B Aarts, et al.
Hepatology International|February 26, 2021
Checkpoint inhibitor induced hepatitis and the relation with liver metastasis and outcome in advanced melanoma patientsMaaike Biewenga, Monique K van der Kooij, Michel W J M Wouters, et al.
Cancers|November 26, 2022
Systemic Therapy in Advanced Nodular Melanoma versus Superficial Spreading Melanoma: A Nation-Wide Study of the Dutch Melanoma Treatment RegistryDaan Jan Willem Rauwerdink, Remco van Doorn, Jos van der Hage, et al.
American Journal of Clinical Oncology|December 17, 2020
Nationwide Outcomes of Advanced Melanoma According to BRAFV600 StatusJesper van Breeschoten, Michel W J M Wouters, Liesbeth C de Wreede, et al.
British Journal of Cancer|January 26, 2021
First-line BRAF/MEK inhibitors versus anti-PD-1 monotherapy in BRAF<sup>V600</sup>-mutant advanced melanoma patients: a propensity-matched survival analysisJesper van Breeschoten, Michel W J M Wouters, Doranne L Hilarius, et al.
ESMO Open|December 2, 2021
Trends in survival and costs in metastatic melanoma in the era of novel targeted and immunotherapeutic drugsM G Franken, B Leeneman, M J B Aarts, et al.
JCO Precision Oncology|September 21, 2022
<i>BRAF</i> and <i>NRAS</i> Mutation Status and Response to Checkpoint Inhibition in Advanced MelanomaOlivier J van Not, Willeke A M Blokx, Alfons J M van den Eertwegh, et al.
European Journal of Cancer (Oxford, England : 1990)|October 23, 2025
Induction therapy with BRAF/MEK inhibitors versus upfront ipilimumab/nivolumab in poor prognostic advanced melanomaM Bloem, A J M van den Eertwegh, J B A G Haanen, et al.
Pageof 13

Showing results (61-70 of 123) with videos related to

Sort By:
Pageof 13
Cancer Immunology, Immunotherapy : CII|March 28, 2021
Clinical outcome of patients with metastatic melanoma of unknown primary in the era of novel therapyDanielle Verver, Dirk J Grünhagen, Alexander C J van Akkooi, et al.
Cancers|May 13, 2020
Surgery for Unresectable Stage IIIC and IV Melanoma in the Era of New Systemic TherapyStephanie A Blankenstein, Maureen J B Aarts, Franchette W P J van den Berkmortel, et al.
Cancers|September 28, 2021
Sex-Based Differences in Treatment with Immune Checkpoint Inhibition and Targeted Therapy for Advanced Melanoma: A Nationwide Cohort StudyMonique K van der Kooij, Olaf M Dekkers, Maureen J B Aarts, et al.
Hepatology International|February 26, 2021
Checkpoint inhibitor induced hepatitis and the relation with liver metastasis and outcome in advanced melanoma patientsMaaike Biewenga, Monique K van der Kooij, Michel W J M Wouters, et al.
Cancers|November 26, 2022
Systemic Therapy in Advanced Nodular Melanoma versus Superficial Spreading Melanoma: A Nation-Wide Study of the Dutch Melanoma Treatment RegistryDaan Jan Willem Rauwerdink, Remco van Doorn, Jos van der Hage, et al.
American Journal of Clinical Oncology|December 17, 2020
Nationwide Outcomes of Advanced Melanoma According to BRAFV600 StatusJesper van Breeschoten, Michel W J M Wouters, Liesbeth C de Wreede, et al.
British Journal of Cancer|January 26, 2021
First-line BRAF/MEK inhibitors versus anti-PD-1 monotherapy in BRAF<sup>V600</sup>-mutant advanced melanoma patients: a propensity-matched survival analysisJesper van Breeschoten, Michel W J M Wouters, Doranne L Hilarius, et al.
ESMO Open|December 2, 2021
Trends in survival and costs in metastatic melanoma in the era of novel targeted and immunotherapeutic drugsM G Franken, B Leeneman, M J B Aarts, et al.
JCO Precision Oncology|September 21, 2022
<i>BRAF</i> and <i>NRAS</i> Mutation Status and Response to Checkpoint Inhibition in Advanced MelanomaOlivier J van Not, Willeke A M Blokx, Alfons J M van den Eertwegh, et al.
European Journal of Cancer (Oxford, England : 1990)|October 23, 2025
Induction therapy with BRAF/MEK inhibitors versus upfront ipilimumab/nivolumab in poor prognostic advanced melanomaM Bloem, A J M van den Eertwegh, J B A G Haanen, et al.
Pageof 13